lung
-
Abbott receives FDA approval for ALK gene test for lung cancer therapy selection
Abbott announced it has received approval from the US Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC). The new…
lung | 27 August 2011
-
South Korea: Non-small cell lung cancer drug market trends
South Korea’s advanced medical and research infrastructure creates opportunities for pharmaceutical companies to expand current drug options and increase survival rates.
lung | 01 July 2011
-
Abbott submits molecular test for lung cancer therapy
Abbott announced it filed premarket approval applications to the US FDA and the Japanese Ministry of Health, Labour, and Welfare for a new molecular diagnostic test designed to detect abnormal gene rearrangements in non-small-cell lung cancer (NSCLC)…
lung | 23 May 2011
-
Genentech to present progress in advanced skin, lung and ovarian cancer treatment
Genentech, a member of the Roche Group, announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the Amer…
lung | 19 May 2011
-
Sanofi-aventis, Regeneron report phase 3 lung cancer treatment trial results
Sanofi-aventis and Regeneron Pharmaceuticals Inc announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC). The data showed that …
lung | 11 March 2011
-
Roche and OSI Pharmaceuticals Gain Approval for Cancer Treatment
Roche and OSI Pharmaceuticals have gained US Food and Drug Administration (FDA) approval for the use of Tarceva as a maintenance treatment for non-small cell lung cancer. The FDA's decision comes despite an earlier negative opinion from its advis…
lung | 26 May 2010
-
AstraZeneca Receives Marketing Authorization for Lung Cancer Drug
AstraZeneca has announced that the European Commission has granted marketing authorization for an oral anti-cancer drug. Iressa is used for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activatin…
lung | 01 August 2009
-
CanBas and Takeda Advance Cancer Drug into Phase II Trial
CanBas and Takeda Pharmaceutical Company have announced the advancement of CBP501 into Phase II clinical trials for the treatment of patients with non-small cell lung cancer (NSCLC). Current pre-clinical data suggest that the drug has the potential t…
lung | 23 July 2009
-
Novartis to acquire Nektar Therapeutics pulmonary business unit
Novartis has strengthened its capabilities for developing medicines that can be delivered via the lungs through a definitive agreement to acquire the pulmonary drug delivery business unit of Nektar Therapeutics for $115 million in cash. Important…
lung | 28 October 2008
-
Updates on COPD patients receiving Seretide/Advair
Study results show that treatment with Seretide/Advair (salmeterol/fluticasone propionate 50/500mcg) can slow the progression of chronic obstructive pulmonary disease (COPD) by significantly lowering a patient’s rate of lung function decline compar…
lung | 26 August 2008
